Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

NCT04740996 · clinicaltrials.gov ↗

UNKNOWN

Status

30

Enrollment

UNKNOWN

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

Shi Yuankai